Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
December 2, 2018
- Treatment with APL-2 in eculizumab-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) resulted in broad control of hemolysis and normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline
- Previously transfusion-dependent patients did not require any transfusions during maintenance treatment with APL-2
- Rapid and durable normalization Lactate Dehydrogenase, Reticulocyte Count and Total Bilirubin was achieved
Interim results from the ongoing PADDOCK study evaluating 270mg subcutaneous APL-2 administered daily are presented. Data are presented for 19 patients at baseline, 15 patients on therapy at day 85 and 10 patients at day 169.
“There remains a significant unmet need in PNH driven by extravascular hemolysis, which is not addressed by C5 inhibitors such as eculizumab,” said Dr.
These data will be presented by Dr. Raymond SM Wong of the
“APL-2 shows meaningful improvement in hematological parameters in ways not seen with standard of care C5 inhibition,” said Dr.
Poster Presentation 1: Inhibition of C3 with APL-2 Results in Normalization of Markers of Intravascular and Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Session Name: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Poster II
Date: Sunday, December 2, 2018
Presentation Time: 6:
Location: San Diego Convention Center, Hall GH
PADDOCK is an open-label, dose-escalation trial designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of multiple doses of APL-2, in patients with PNH, a rare and serious condition affecting the bone marrow. Data to be presented demonstrates:
- Hemoglobin: Broad control of hemolysis, both intravascular and extravascular, led to significant and sustained increases in hemoglobin in the absence of transfusions. The baseline Hb was 8.0 g/dL (n=19) which increased to 10.8 g/dL (n=19) and 12.2 g/dL (n=15) at Days 29 and 85, respectively. In the 12 months prior to screening, subjects received an average of 8.7 units pRBCs (range 0-28). Transfusion independence was achieved while on APL-2 maintenance therapy with the exception of one patient with severe aplastic anemia at Day 364
- Hemolysis Control: Systemic inhibition of C3 with APL-2 controls both intravascular and extravascular hemolysis in PNH patients as demonstrated by rapid and durable normalization of LDH, total bilirubin, and reticulocytes, all markers of hemolysis
About Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, potentially life-threatening disease characterized by complement-mediated hemolysis with or without hemoglobinuria, an increased susceptibility to thrombotic episodes and/or some degree of bone marrow dysfunction. A significant subset of patients treated with the current standard of care still suffer from debilitating anemia and transfusion dependence.
APL-2 is designed to inhibit the complement cascade centrally at C3 and may have the potential to treat a wide range of complement-mediated diseases more effectively than is possible with partial inhibitors of complement. APL-2 is a synthetic cyclic peptide conjugated to a polyethylene glycol (PEG) polymer that binds specifically to C3 and C3b, effectively blocking all three pathways of complement activation (classical, lectin, and alternative). To date, APL-2 has generally been well-tolerated. No significant infections have been observed in trials involving the systemic administration of APL-2, including the trials in PNH, AIHA or other trials.
In hematologic diseases, Apellis is currently evaluating APL-2 in two Phase 1b trials (PHAROAH and PADDOCK) for systemic administration in paroxysmal nocturnal hemoglobinuria (PNH). Previously reported interim data from these trials showed improvements in lactate dehydrogenase and hemoglobin levels in patients who are suboptimal responders to eculizumab and untreated patients, respectively. Apellis is also testing APL-2 for systemic administration in a Phase 2 clinical trial in autoimmune hemolytic anemia (AIHA) and a Phase 2 clinical trial in complement dependent nephropathies, as well as a Phase 3 trial for patients with PNH. For additional information regarding our clinical trials, visit www.apellis.com/clinical-trials.html.
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements relating to the implications of preliminary clinical data. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether preliminary or interim results from a clinical trial will be predictive of the final results of the trial; whether results obtained in preclinical studies and clinical trials such as the results reported in this release will be indicative of results that will be generated in future clinical trials; whether APL-2 will successfully advance through the clinical trial process on a timely basis, or at all; whether the results of such clinical trials will warrant regulatory submissions and whether APL-2 will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies for GA, PNH or any other indication; whether, if Apellis’ products receive approval, they will be successfully distributed and marketed; and other factors discussed in the “Risk Factors” section of Apellis’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 13, 2018 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
1 McKinley CE, Richards SJ, Munir T, Griffin M, Mitchell LD, Arnold L, Riley K, Copeland N, Newton DJ, Hill A, Hillmen P. Extravascular hemolysis due to C3-loading in patients with PNH treated with eculizumab: defining the clinical syndrome. Blood. 2017:130:3471.
Source: Apellis Pharmaceuticals, Inc.